FY2024 EPS Estimates for Agilent Technologies, Inc. Lifted by Analyst (NYSE:A)

Agilent Technologies, Inc. (NYSE:A) – Stock analysts at Zacks Research boosted their FY2024 earnings estimates for Agilent Technologies in a research note issued to investors on Wednesday, September 11th. Zacks Research analyst S. Mete now expects that the medical research company will earn $5.24 per share for the year, up from their prior estimate of $5.23. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.24 per share. Zacks Research also issued estimates for Agilent Technologies’ Q4 2024 earnings at $1.41 EPS, Q1 2025 earnings at $1.38 EPS, Q3 2025 earnings at $1.40 EPS, Q1 2026 earnings at $1.55 EPS, Q2 2026 earnings at $1.46 EPS, Q3 2026 earnings at $1.62 EPS and FY2026 earnings at $6.24 EPS.

A number of other research analysts have also recently commented on the company. Bank of America raised their target price on Agilent Technologies from $140.00 to $147.00 and gave the company a “neutral” rating in a research note on Thursday, August 22nd. Citigroup upped their target price on shares of Agilent Technologies from $150.00 to $165.00 and gave the stock a “buy” rating in a research report on Thursday, August 22nd. UBS Group lifted their price target on shares of Agilent Technologies from $141.00 to $150.00 and gave the company a “neutral” rating in a research report on Thursday, August 22nd. Wells Fargo & Company started coverage on shares of Agilent Technologies in a report on Tuesday, August 27th. They issued an “overweight” rating and a $157.00 price objective on the stock. Finally, JPMorgan Chase & Co. lowered their target price on shares of Agilent Technologies from $165.00 to $155.00 and set an “overweight” rating for the company in a report on Thursday, May 30th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, Agilent Technologies presently has a consensus rating of “Moderate Buy” and a consensus price target of $141.60.

Agilent Technologies Stock Performance

Shares of A stock opened at $137.31 on Thursday. The firm has a market capitalization of $40.06 billion, a price-to-earnings ratio of 32.46, a PEG ratio of 6.43 and a beta of 1.05. The stock has a fifty day moving average of $136.75 and a 200 day moving average of $139.18. Agilent Technologies has a 52 week low of $96.80 and a 52 week high of $155.35. The company has a quick ratio of 1.37, a current ratio of 1.78 and a debt-to-equity ratio of 0.36.

Agilent Technologies (NYSE:A) last released its earnings results on Wednesday, August 21st. The medical research company reported $1.32 earnings per share for the quarter, topping analysts’ consensus estimates of $1.26 by $0.06. Agilent Technologies had a return on equity of 25.26% and a net margin of 21.75%. The company had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.56 billion. During the same quarter in the previous year, the company posted $1.43 EPS. Agilent Technologies’s quarterly revenue was down 5.6% compared to the same quarter last year.

Insider Buying and Selling

In related news, CEO Padraig Mcdonnell sold 1,958 shares of the stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $140.00, for a total transaction of $274,120.00. Following the completion of the sale, the chief executive officer now owns 26,076 shares in the company, valued at $3,650,640. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.33% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Crewe Advisors LLC increased its stake in Agilent Technologies by 114.8% in the 2nd quarter. Crewe Advisors LLC now owns 189 shares of the medical research company’s stock worth $25,000 after buying an additional 101 shares during the period. Livelsberger Financial Advisory bought a new stake in shares of Agilent Technologies during the fourth quarter valued at approximately $26,000. Ridgewood Investments LLC purchased a new stake in shares of Agilent Technologies in the second quarter valued at approximately $29,000. Rise Advisors LLC grew its stake in Agilent Technologies by 527.8% in the first quarter. Rise Advisors LLC now owns 226 shares of the medical research company’s stock worth $33,000 after purchasing an additional 190 shares in the last quarter. Finally, YHB Investment Advisors Inc. purchased a new position in Agilent Technologies during the 1st quarter worth $34,000. Hedge funds and other institutional investors own 87.42% of the company’s stock.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.